Analyst Price Target is $18.50
▲ +186.38% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Larimar Therapeutics in the last 3 months. The average price target is $18.50, with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 186.38% upside from the last price of $6.46.
Current Consensus is
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Larimar Therapeutics. This Buy consensus rating has held steady for over two years.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Read More